KAO JOHN E sold $4.9M of ALHC

KAO JOHN E (Chief Executive Officer) sold 385,270 shares of Alignment Healthcare, Inc. (ALHC) at $12.68 ($4.89M total) on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Sep 12, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Bearish
medium confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCBearishMed
01

Why it matters

The sale represents a $4.9M reduction in CEO holdings, which may be interpreted by investors as a bearish sign.

02

Market read

Insider sales are closely watched; this filing could influence short-term price action.

03

What to watch

Pre-arranged 10b5-1 plans are often used for tax planning and may not reflect sentiment.

Relevance 5/10Novelty 7/10Timing: after-market 2026-09-11

Background

Form 4 filing discloses insider transactions required by SEC; provides first public notice of the sale.

Company-level read

Ticker impact

$ALHCBearishMedium confidence
Context

CEO sold 385,270 shares for $4.9M via 10b5-1 plan on 2026-09-11

Expected impact

Potential modest downside pressure in near-term trading.

Evidence & confidence

Large insider sell by CEO, executed under pre-arranged plan, indicates possible liquidity need or valuation concerns.

Market effects

May affect healthcare services sector sentiment as insider activity is monitored.

Limited to US markets where ALHC trades.

Low

Counterpoint

Insider sale could be routine liquidity event, not a negative signal.

Key entities

  • KAO JOHN E

    Chief Executive Officer of Alignment Healthcare, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.